According to projections, the global market for Gene Therapy in CNS Disorders will reach a value of US$ 8.2 billion in 2023 and US$ 113.04 billion by 2033, with a compound annual growth rate (CAGR) of 30% between 2023 and 2033. During the period of 2018 to 2022, the market for gene therapy in CNS illnesses had a CAGR of 19%.
The increasing prevalence of CNS disorders, especially neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, is a significant driver of this growth. With the aging of the global population, the incidence of these conditions is expected to rise, resulting in a significant healthcare burden and driving demand for effective treatments.
For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16744
Moreover, the growing investment in gene therapy research and development is expected to hasten the development of new therapies for CNS disorders. Regulatory agencies such as the FDA have created accelerated pathways for the approval and review of gene therapy treatments, facilitating faster development and commercialization of these therapies.
Key Takeaways from the Market Study
- The Gene Therapy in CNS Disorder market increased at a 19% CAGR from 2018 to 2022.
- From 2023 to 2033, the global Gene Therapy in CNS Disorder market is predicted to develop at a 30% CAGR.
- The Gene Therapy in CNS Disorder Market is anticipated to reach US$ 113.04 billion by 2033.
- Hospitals have the biggest market share, according to the FMI research.
- North America is estimated to have 40% of the market for Gene Therapy in CNS Disorders.
- The East & South Asia market is expected to grow significantly throughout the forecast period, accounting for 20% of the total.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16744
Market Competition
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
- In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.
More Insights Available
North America is projected to dominate the Gene Therapy market due to the presence of a well-established healthcare infrastructure, significant investment in gene therapy research and development, and favorable regulatory policies. The United States is expected to contribute the most significant share of the market due to its advanced healthcare system and high incidence of CNS disorders.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16744
Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey
Indication:
- Alzheimer’s Disease
- Huntington’s Disease
- Parkinson’s Disease
- Batten Disease
Type:
- Ex Vivo
- In Vivo
End User:
- Hospitals
- Speciality Clinics
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
